Certara, Inc. (NASDAQ:CERT) Given Consensus Rating of “Hold” by Brokerages

by · The Markets Daily

Certara, Inc. (NASDAQ:CERT – Get Free Report) has been given an average rating of “Hold” by the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.85.

CERT has been the subject of several recent analyst reports. Morgan Stanley cut their price objective on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. KeyCorp cut their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. Stephens cut their price objective on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Robert W. Baird cut their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th.

Get Our Latest Stock Report on Certara

Certara Trading Up 16.1%

CERT opened at $6.05 on Wednesday. Certara has a twelve month low of $4.45 and a twelve month high of $13.88. The company has a 50-day simple moving average of $5.59 and a 200 day simple moving average of $7.12. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $941.20 million, a price-to-earnings ratio of -60.50 and a beta of 1.49.

Certara (NASDAQ:CERT – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. During the same period in the prior year, the company earned $0.14 EPS. The company’s revenue for the quarter was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Analysts predict that Certara will post 0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Dixon Mitchell Investment Counsel Inc. acquired a new position in Certara during the third quarter worth about $10,587,000. Fort Washington Investment Advisors Inc. OH raised its stake in Certara by 133.4% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock worth $20,024,000 after acquiring an additional 1,299,109 shares in the last quarter. Kopion Asset Management LLC raised its stake in Certara by 49.9% during the fourth quarter. Kopion Asset Management LLC now owns 982,710 shares of the company’s stock worth $8,658,000 after acquiring an additional 327,064 shares in the last quarter. Topline Capital Management LLC acquired a new position in Certara during the third quarter worth about $6,678,000. Finally, Brown Brothers Harriman & Co. raised its stake in Certara by 34.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,764,034 shares of the company’s stock worth $45,996,000 after acquiring an additional 972,669 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

(Get Free Report)

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.

Read More